AlphAIAlphAI — Financial news for AI agents
tradingview.com$XGN

Exagen Inc. (XGN) Q3 Revenue Rose 7% to $18.4M; 2026 Guidance Reiterated

Exagen Inc. (XGN) reported Q3 revenue of $18.4M, up 7% YoY, with year-to-date revenue growth of 11%. Net loss decreased 12% and adjusted EBITDA loss improved over 30%. The company reiterated its 2026 revenue guidance of $72M to $75M.

Original reporting
tradingview.com
Published Nov 10, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Exagen Inc. (XGN) Q3 Revenue Rose 7% to $18.4M; 2026 Guidance Reiterated — source image
Source · tradingview.com
Decision brief

The 30-second read

$XGNBearishMed
01

Why it matters

The earnings beat and guidance reiteration provide fresh data for traders assessing short‑term price moves.

02

Market read

New earnings data for a micro‑cap biotech could trigger modest price movement.

03

What to watch

Potential upcoming regulatory approvals or new contract wins could amplify impact.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

Exagen Inc. (XGN) released its third‑quarter results, highlighting revenue growth and loss reduction while reaffirming full‑year guidance.

Company-level read

Ticker impact

$XGNBearishMedium confidence
Context

Exagen reported Q3 revenue of $18.4M, up 7%, and reiterated 2026 guidance of $72M‑$75M.

Expected impact

likely modest upside as market prices in improved earnings trends

Evidence & confidence

The company showed top‑line growth and loss reduction, but absolute numbers remain small for a micro‑cap.

Market effects

Sector

Shows continued revenue growth in the molecular diagnostics niche.

Regional

Limited to U.S. biotech micro‑cap segment.

Global

Minimal broader market effect.

Counterpoint

What could challenge this read

Despite growth, the small scale may not justify a price rally; investors may remain cautious.

Key entities

  • company
    Exagen Inc.

    Molecular diagnostics company reporting Q3 results.

Read at source← All news

Related articles

$XGNLow

Exagen Inc. Reports Third Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% November 10, 2026 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precisio

SEC EDGAR 8-K
$XGNMedAI 8/10

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.

yahoo.com
$XGNMedAI 8/10

Exagen Inc. Q2 2026 Earnings Call Summary

Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.

yahoo.com
$XGNMed

Exagen Inc. Reports Second Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million August 4,

SEC EDGAR 8-K